Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arcus Biosciences, Inc. (NYSE:RCUS), a biopharmaceutical company focused on cancer treatments, announced the grant of equity awards to six new employees. The awards include options to purchase a total of 17,600 shares at an exercise price of $19.31 as of April 24, 2023. Additionally, they received restricted stock units for 8,800 shares, under the 2020 Inducement Plan approved in January 2020.
The company aims to develop innovative cancer therapies in collaboration with industry partners and has six investigational medicines in clinical studies targeting various biological pathways.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to nine new employees. A total of 34,000 options at an exercise price of $17.36 per share and 15,200 restricted stock units were issued. The options were granted under the company’s 2020 Inducement Plan, which was approved in January 2020.
Arcus is focused on developing innovative therapies for cancer treatment, examining molecules targeting various biological pathways. Founded in 2015, it currently has six investigational medicines in clinical studies.
Arcus Biosciences (NYSE:RCUS) announced the grant of stock options and restricted stock units to eight new employees as part of its 2020 Inducement Plan. A total of 66,200 options were granted at an exercise price of $17.78, the closing price on March 8, 2023, along with 33,100 restricted stock units. This move aims to attract talent in the clinical-stage biopharmaceutical sector, focusing on innovative therapies for cancer treatment. Founded in 2015, Arcus is advancing six investigational drugs targeting various cancer pathways.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, announced participation in a fireside chat at the Barclays Global Healthcare Conference on March 14, 2023, at 8:30 a.m. ET in Miami Beach, Florida. The chat will be accessible via live webcast through the Investors & Media section of the Arcus website.
Founded in 2015, Arcus focuses on developing innovative therapies for cancer, including investigational drugs targeting TIGIT and PD-1. The company aims to enhance the efficacy of cancer treatment through unique biological combinations.